Analysts Issue Forecasts for APLS FY2030 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a report released on Wednesday, February 25th. HC Wainwright analyst D. Tsao expects that the company will post earnings of $1.97 per share for the year. HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share.

A number of other equities analysts have also recently weighed in on APLS. William Blair reaffirmed an “outperform” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 15th. TD Cowen reduced their price objective on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Mizuho lowered their target price on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Royal Bank Of Canada dropped their target price on shares of Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating for the company in a report on Wednesday. Finally, JPMorgan Chase & Co. reduced their price target on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Twelve analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $32.61.

Apellis Pharmaceuticals Trading Down 3.2%

NASDAQ:APLS opened at $21.42 on Thursday. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $30.48. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The stock has a fifty day moving average price of $23.13 and a two-hundred day moving average price of $23.83. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of 20.02 and a beta of 0.26.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a return on equity of 9.31% and a net margin of 2.23%.The business had revenue of $199.91 million during the quarter, compared to analysts’ expectations of $199.28 million. During the same period last year, the firm earned ($0.29) EPS. The company’s quarterly revenue was down 5.9% compared to the same quarter last year.

Insider Activity

In other Apellis Pharmaceuticals news, insider Nur Nicholson sold 7,725 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $168,173.25. Following the completion of the transaction, the insider owned 71,118 shares in the company, valued at approximately $1,548,238.86. The trade was a 9.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Timothy Eugene Sullivan sold 10,287 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $223,947.99. Following the completion of the sale, the chief financial officer directly owned 93,901 shares in the company, valued at $2,044,224.77. This trade represents a 9.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 120,537 shares of company stock worth $2,608,532 in the last three months. Company insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of large investors have recently bought and sold shares of APLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 207.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company’s stock worth $667,000 after acquiring an additional 19,944 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Apellis Pharmaceuticals by 26.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock worth $6,730,000 after purchasing an additional 64,742 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Apellis Pharmaceuticals by 4.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company’s stock worth $4,869,000 after purchasing an additional 9,747 shares in the last quarter. Focus Partners Wealth raised its stake in Apellis Pharmaceuticals by 118.4% in the 1st quarter. Focus Partners Wealth now owns 21,883 shares of the company’s stock valued at $479,000 after purchasing an additional 11,862 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its stake in shares of Apellis Pharmaceuticals by 1,146.2% during the first quarter. Acadian Asset Management LLC now owns 23,976 shares of the company’s stock valued at $522,000 after buying an additional 22,052 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals News Roundup

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright published a bullish long‑term forecast (FY2030) calling for $1.97 EPS and maintains a “Buy” stance with a $48 price target — a material upside signal that supports a higher valuation for APLS over the next several years.
• Positive Sentiment: Citigroup kept a “Buy” rating despite trimming its target slightly from $45 to $44, leaving a large implied upside; that continued buy conviction from a major shop is supportive for the stock. Article Title
• Positive Sentiment: Q4 results beat consensus: Apellis reported $0.47 EPS vs. an expected loss (~-$0.39) and revenue roughly $199.9M (in line/above estimates). Management highlighted a strong Empaveli launch (sales +50% Y/Y) that helped offset weakness elsewhere. Zacks Q4 Article
• Neutral Sentiment: Multiple earnings‑call transcripts and presentations are available (Yahoo Finance, Seeking Alpha, InsiderMonkey), useful for deeper read‑throughs on guidance, margin commentary and commercial execution. Yahoo Transcript Seeking Alpha InsiderMonkey
• Neutral Sentiment: Short‑interest reports in the feed show “0 shares” and 0 days‑to‑cover — this looks like a reporting/data anomaly and should not be treated as meaningful evidence of a sudden shift in short positioning.
• Negative Sentiment: Royal Bank of Canada trimmed its target to $21 and set a “sector perform” rating, implying the stock may be near fair value in the near term. TickerReport
• Negative Sentiment: Wedbush cut its target from $20 to $18 and moved to “neutral,” which adds downside pressure from a formerly constructive shop and may temper momentum. TickerReport
• Negative Sentiment: Operational nuance: Syfovre sales slipped ~8% in the quarter, a product‑level weakness investors will watch as management discusses commercial durability and growth cadence. Zacks Q4 Article

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.